Time limits apply in California. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — California
California Code of Civil Procedure § 335.1 provides a 2-year statute of limitations for personal injury claims including pharmaceutical product liability. The discovery rule applies — the limitations period begins when the plaintiff discovers or reasonably should have discovered the injury and its connection to Elmiron. California does not have a statute of repose for product liability claims, which is significant given many patients took Elmiron for 10-20+ years.
2 years from discovery of Elmiron-related vision injury
Filing venue
Where to File in California
Federal Elmiron cases from California are transferred to the MDL in the District of New Jersey (MDL No. 2973). California state court claims may proceed independently in Los Angeles, San Francisco, or San Diego Superior Courts. California applies the Kelly/Frye standard for expert admissibility rather than the federal Daubert standard. California's lack of a product liability statute of repose is particularly significant for Elmiron cases where patients used the drug for a decade or more before the retinal toxicity connection was established.
California data
Exposure in California
California population — largest potential Elmiron patient pool of any state, with major urology and ophthalmology treatment centers throughout the state
39.5 million
Source: U.S. Census Bureau 2024
Estimated number of Americans affected by interstitial cystitis — California accounts for approximately 12% based on population share
3-7 million
Source: Interstitial Cystitis Association
Year Emory University researchers first published findings linking long-term Elmiron use to a unique form of pigmentary maculopathy, triggering subsequent lawsuits
2018
Source: Ophthalmology (journal)
Keep reading